Overview: Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines across various regions including Europe, the Middle East, Africa ...

The offer represents a 3.6% increase from the initial offer in January 2025, from 62.5 pence per share to 64.75 pence per share.

Britain's Alliance Pharma said on Monday it has agreed to a sweetened final cash proposal from asset management firm DBAY Advisors, valuing the healthcare group at about 362 million pounds ($467.5 ...

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. Butterfield is one of ...

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name ...

Overview: Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines across various regions including Europe, the Middle East, Africa, the Asia ...

A Wiltshire-based healthcare firm has backed an increased takeover bid worth a whopping £362 million. Alliance Pharma, based at Avonbridge House in Chippenham, has been the subject of an offer worth ...

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk. 20th Feb 2025 3:34 pm RNS Form 8.5 (EPT/RI) -Alliance Pharma plc-Replacement 20th Feb 2025 3:30 pm RNS Form 8.3 ...

Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Tempero ...

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel's website at ...